Clofazimine: an old drug for never-ending diseases

Clofazimine (CFZ), an old hydrophobic riminophenazine, has a wide range of antimycobacterial activity ranging from leprosy to nontuberculous mycobacterial diseases. CFZ has several advantages such as a favorable pharmacokinetic profile, dose-dependent side effects as well as low price. In this narra...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Future microbiology Ročník 15; číslo 7; s. 557 - 566
Hlavní autoři: Riccardi, Niccolò, Giacomelli, Andrea, Canetti, Diana, Comelli, Agnese, Intini, Enrica, Gaiera, Giovanni, Diaw, Mama M, Udwadia, Zarir, Besozzi, Giorgio, Codecasa, Luigi, Biagio, Antonio Di
Médium: Journal Article
Jazyk:angličtina
Vydáno: Future Medicine Ltd 01.05.2020
Témata:
clofazimine
leprosy
MDR-TB
NTM
XDR-TB
ISSN:1746-0913, 1746-0921, 1746-0921
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Clofazimine (CFZ), an old hydrophobic riminophenazine, has a wide range of antimycobacterial activity ranging from leprosy to nontuberculous mycobacterial diseases. CFZ has several advantages such as a favorable pharmacokinetic profile, dose-dependent side effects as well as low price. In this narrative review, we have assessed the clinical development of CFZ, starting from the potential mechanism of actions, to the spectrum of side effects and potential drug–drug interactions, highlighting its current place in therapy and future possible use in leprosy, nontuberculous mycobacterial diseases and drug-resistant tuberculosis.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1746-0913
1746-0921
1746-0921
DOI:10.2217/fmb-2019-0231